Stanford Medicine scientists are studying why even brief trips into space can weaken muscle and heart tissue, mimicking decades of aging on Earth.
Category: Drug Development
Could the avian flu be our next pandemic threat?
What does it mean that H5N1 bird flu, also known as highly pathogenic avian influenza A, is spreading among dairy cows? And how should U.S. health systems — and consumers of milk products — be responding?
Serious talk about moods with bipolar disorder expert Po Wang
Often misunderstood and undertreated, bipolar disorder has received close attention from Stanford Medicine clinicians and researchers for more than 30 years.
One step back: Why the new Alzheimer’s plaque-attack drugs don’t work
A few closely related drugs, all squarely aimed at treating Alzheimer’s disease, have served up what can be charitably described as a lackadaisical performance. Stanford Medicine neurologist Mike Greicius explains why these drugs, so promising in theory, don’t appear to be helping patients much if at all.
Not all about neurons: A new avenue for treating neurodegeneration, injury
Stanford Medicine's Jeffrey Goldberg believes a young, underexplored class of therapies called gliotherapeutics, which target and harness glia, will ultimately provide important new directions for treatment.
Going beyond B cells in the search for a more multi-targeted vaccine
The ultimate goal: a vaccine with coverage so broad it can protect against viruses never before encountered.
Searching for vaccine variability in the land of the flu
The ultimate goal: a vaccine with coverage so broad it can protect against viruses never before encountered.
The hunt for a vaccine that fends off not just a single viral strain, but a multitude
Stanford Medicine researchers are designing vaccines that might protect people from not merely individual viral strains but broad ranges of them. The ultimate goal: a vaccine with coverage so broad it can protect against viruses never before encountered.
What is behind the legal drug crisis in the US?
The cost of branded pharmaceuticals and quality and availability of generic versions are two key issues facing the U.S. marketplace.
Scientists identify ‘Velcro-like’ molecule to potentially treat ALS
A drug created by Stanford Medicine scientists aimed at a ‘Velcro’-like protein reduces ALS symptoms and improves survival in mice.
mRNA medicines: Looking back, and a look forward
Stanford Medicine experts discuss the past successes and future potential of mRNA as a new type of medicine or treatment.
What’s the deali-O with new weight loss drugs? Part 1
Stanford Medicine researchers weigh in on the promise and peril of increasingly popular diabetes drugs being used for weight loss.
Bioluminescence helps researchers develop cancer drugs for brain
A bioluminescent indicator glows when a cancer drug is active inside the brain, identifying which medications cross the blood-brain barrier.
Making the invisible visible to improve heart surgery outcomes
Scientists find a way in mice to illuminate the cardiac conduction system during surgery to prevent unintended damage to healthy tissue.
Basic biochemistry research leads to heart-saving drug
Researchers at Stanford Medicine discovered the mechanism for a heart condition and developed a drug to treat it.
Machine learning could enable faster, less costly epilepsy drugs
Researchers created an algorithm to determine if mice have epilepsy and whether they have been treated with seizure drugs.